Passage Bio to Report Second Quarter 2022 Financial Results on August 4, 2022
July 28 2022 - 7:30AM
Passage Bio, Inc. (NASDAQ: PASG), a clinical-stage genetic
medicines company focused on developing transformative therapies
for central nervous system (CNS) disorders, today announced that it
will host a conference call and live webcast at 8:30 a.m. ET on
Thursday, August 4, 2022, to report its second quarter 2022
financial results and discuss recent business highlights.
To access the live conference call and webcast, please register
here. The archived webcast will be available on Passage Bio's
website approximately two hours after the completion of the event
and for 30 days following the call.
About Passage Bio
Passage Bio (Nasdaq: PASG) is a clinical-stage genetic medicines
company on a mission to provide life-transforming therapies for
patients with CNS diseases with limited or no approved treatment
options. Our portfolio spans pediatric and adult CNS indications,
and we are currently advancing three clinical programs in GM1
gangliosidosis, Krabbe disease and frontotemporal dementia with
several additional programs in preclinical development. Based in
Philadelphia, PA, our company has established a strategic
collaboration and licensing agreement with the renowned University
of Pennsylvania’s Gene Therapy Program to conduct our discovery and
IND-enabling preclinical work. Through this collaboration, we have
enhanced access to a broad portfolio of gene therapy candidates and
future gene therapy innovations that we then pair with our deep
clinical, regulatory, manufacturing and commercial expertise to
rapidly advance our robust pipeline of optimized gene therapies. As
we work with speed and tenacity, we are always mindful of patients
who may be able to benefit from our therapies. More information is
available at www.passagebio.com.
For further information, please contact:
Passage Bio Investors:
Stuart HendersonPassage
Bio267-866-0114shenderson@passagebio.com
Passage Bio Media:
Mike BeyerSam Brown Inc. Healthcare
Communications312-961-2502MikeBeyer@sambrown.com
Passage Bio (NASDAQ:PASG)
Historical Stock Chart
From Mar 2024 to Apr 2024
Passage Bio (NASDAQ:PASG)
Historical Stock Chart
From Apr 2023 to Apr 2024